肠癌基因突变与靶向治疗方案

2017年07月17日

标签：

1	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. Cunningham D et al. N Engl J Med. 2004 PMID: 15269313
2	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Chung KY et al. J Clin Oncol. 2005 PMID: 15677699
3	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. Van Cutsem E et al. N Engl J Med. 2009 PMID: 19339720
4	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Price TJ et al. Lancet Oncol. 2014 PMID: 24739896
5	Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Van Cutsem E et al. J Clin Oncol. 2007 PMID: 17470858
6	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M et al. J Clin Oncol. 2010 PMID: 20921462
7	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Douillard JY et al. J Clin Oncol. 2010 PMID: 20921465
8	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Price TJ et al. Lancet Oncol. 2014 PMID: 24739896
9	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Grothey A et al. Lancet. 2013 PMID: 23177514
10	B-Raf and the inhibitors: from bench to bedside. Huang T et al. J Hematol Oncol. 2013 PMID: 23617957
11	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F et al. J Clin Oncol. 2008 PMID: 19001320
12	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P et al. J Clin Oncol. 2009 PMID: 19884556
13	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W et al. Lancet Oncol. 2010 PMID: 20619739
14	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Corcoran RB et al. Cancer Discov. 2012 PMID: 22448344
15	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Yaeger R et al. Clin Cancer Res. 2015 PMID: 25589621
16	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. Kakavand H et al. Clin Cancer Res. 2015 PMID: 25609064
17	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S et al. Sci Transl Med. 2015 PMID: 25787767
18	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Le DT et al. N Engl J Med. 2015 PMID: 26028255
19	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Loi S et al. Clin Cancer Res. 2016 PMID: 26515496
20	Bendell et al. Abstract# 3502, ASCO 2016
21	Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT et al. N Engl J Med. 2012 PMID: 22663011
22	Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Watanabe M et al. Cancer Sci. 2013 PMID: 23438367
23	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. Kakavand H et al. Clin Cancer Res. 2015 PMID: 25609064
24	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S et al. Sci Transl Med. 2015 PMID: 25787767
25	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Le DT et al. N Engl J Med. 2015 PMID: 26028255
26	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Loi S et al. Clin Cancer Res. 2016 PMID: 26515496
27	Bendell et al. Abstract# 3502, ASCO 2016
28	Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Urick ME et al. Clin Cancer Res. 2011 PMID: 21690569
29	Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT et al. N Engl J Med. 2012 PMID: 22663011
30	Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Watanabe M et al. Cancer Sci. 2013 PMID: 23438367
31	Trametinib: first global approval. Wright CJ et al. Drugs. 2013 PMID: 23846731
32	Germann et al. Abstract# 4693, AACR 2015
33	Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Song EK et al. Int J Cancer. 2015 PMID: 25242168
34	Strickler et al. Abstract# 3548, ASCO 2016
35	Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Wilhelm SM et al. Int J Cancer. 2011 PMID: 21170960
36	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Grothey A et al. Lancet. 2013 PMID: 23177514
37	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Le DT et al. N Engl J Med. 2015 PMID: 26028255
38	Pembrolizumab. Khoja L et al. J Immunother Cancer. 2014 PMID: 26288737
39	Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Urick ME et al. Clin Cancer Res. 2011 PMID: 21690569
40	Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT et al. N Engl J Med. 2012 PMID: 22663011
41	Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Watanabe M et al. Cancer Sci. 2013 PMID: 23438367
42	Trametinib: first global approval. Wright CJ et al. Drugs. 2013 PMID: 23846731
43	Germann et al. Abstract# 4693, AACR 2015
44	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Williams CB et al. Onco Targets Ther. 2015 Dec 1;8:3561-4. doi: 10.2147/OTT.S90766. PMID: 26664139
45	LX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.Tutuka CSA et al., Mol Cancer. 2017 Jun 28;16(1):112. doi: 10.1186/s12943-017-0684-x. PMID: 28659148

阅读数：6896

热门标签

肿瘤资讯治疗药物治疗指南中医食疗治疗技术肿瘤知识基因技术肿瘤词典公司新闻治疗案例专家观点临床试验

文章排行

专栏文章

目录